Deutsche Bank’s Silence Therapeutics SLN Stock Holding History

Deutsche Bank’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-620	Closed	-$6.09K	–	3696
2023 Q3	$6.09K	Hold	620	–	–	﹤0.01%	3596
2023 Q2	$3.41K	Hold	620	–	–	﹤0.01%	3714
2023 Q1	$3.84K	Sell	620 -3,333	-84%	-$39.3K	﹤0.01%	3839
2022 Q4	$60.3K	Hold	3,953	–	–	﹤0.01%	3520
2022 Q3	$40K	Hold	3,953	–	–	﹤0.01%	3648
2022 Q2	$47K	Hold	3,953	–	–	﹤0.01%	3780
2022 Q1	$75K	Buy	+3,953	New	+$78.8K	﹤0.01%	3688

Other funds holding SLN

LOAME

Lombard Odier Asset Management (Europe) London, United Kingdom $1.85B AUM 27.05% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Deutsche Bank's SLN Position: Q4 2023 in Review

Deutsche Bank sold out of Silence Therapeutics (SLN) in Q4 2023, closing a stake of 620 shares — an estimated $6.09K sold.

Deutsche Bank first reported a position in SLN in Q1 2022 and held it in 7 quarters. The position peaked at $75K in Q1 2022. 34 funds tracked by Wall St. Rank hold SLN as of Q4 2023.

Deutsche Bank reported no remaining Silence Therapeutics position as of Q4 2023 after selling out during the quarter.
Deutsche Bank sold 620 Silence Therapeutics shares in Q4 2023, an estimated $6.09K.
Deutsche Bank first reported a position in Silence Therapeutics in Q1 2022 and held it in 7 quarters.
Deutsche Bank's Silence Therapeutics position peaked at $75K in Q1 2022.
34 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2023.

Based on Deutsche Bank's 13F filing for Q4 2023, filed 14 Feb 2024.